Physician profile
Mark Kummer
NPI 1487732640
$1,858.89
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $34.84 · 2021: $66.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $689.46 | 2019 | |
| Novo Nordisk INC | $241.34 | 2019 | |
| Dexcom, INC. | $178.20 | 2019-2020 | |
| Medtronic Minimed, INC. | $162.37 | 2019 | |
| Insulet Corporation | $143.96 | 2019 | |
| Lilly USA, LLC | $109.28 | 2019 | |
| Tandem Diabetes Care, INC. | $106.85 | 2019-2021 | |
| Eisai INC. | $78.98 | 2019 | |
| Merck Sharp & Dohme LLC | $62.57 | 2019 | |
| Sandoz INC. | $24.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.20 | 2019 | |
| Abbvie INC. | $13.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.64 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.